UCLA Health at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
UCLA Health brings 2 presentations to ENA 2026 in Barcelona. Its program spans immunotherapy and antibody-drug conjugates in the clinic. It reports first-in-human results for AT-1965, a CMTR2 inhibitor and B-cell activating immunotherapy, and covers bispecific antibody-drug conjugates.
| Organization | ENA 2026 Attendance |
|---|---|
UCLA Health Los Angeles, CA | |
Academic health system of the University of California, Los Angeles, providing hospital and cancer care and clinical trials. | Talk Wed Nov 18 3:32–3:40pm Talk Thu Nov 19 12:10–12:30pm |
Find decision makers at UCLA Health
Tell us what you sell and we’ll find the people at UCLA Health most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction